These findings might have clinical implications as a potential predictive marker, since recently updated data from the RTOG 9402 trial showed that IDH mutations predict the benefit of adjuvant chemotherapy in grade III glioma [32]. This evidence concerns the gene IDH2 and central nervous system cancer.